Efficacy and safety of liquid nitrogen cryotherapy for treatment of Barrett’s esophagus

Table 1 Characteristics of the entire cohort and the subset evaluated for efficacy n (%)

	Patients analyzed for efficacy n = 33	Entire cohort n = 45
Age, mean ± SD, yr	66 ± 8.7 (range 47-80)	66 ± 8.7 (range 47-87)
Age > 65 yr	17 (52)	22 (49)
Male gender	21 (64)	32 (71)
Barrett’s length, mean ± SD, in cm	3.3 ± 2.1 (range 0.8-7)	3.4 ± 2.2 (range 0.8-8)
Short segment (≤ 3 cm)	58%	56%
Long segment (4-10 cm)	42%	44%
History of ablative therapy	6 (18)	12 (27)
IM at baseline	5 (15)	7 (16)
LGD at baseline	5 (15)	7 (16)
HGD at baseline	15 (45)	19 (42)
IMC at baseline	8 (24)	12 (27)
Years observed, mean ± SD, yr	2.3 ± 1.1 yr (range 1-4)	Entire study duration (4 yr)

LGD: Low-grade dysplasia; HGD: High-grade dysplasia; IMC: Intramucosal adenocarcinoma.

Table 2 Treatment response

	Pathology after cryotherapy treatments
Baseline Pathology	Complete regression	IM	LGD	HGD	IMC	Total
IM	4	1	0	0	0	5
LGD	3	2	0	0	0	5
HGD	5	8	1	1	0	15
IMC	4	2	0	0	2	8

HGD: High-grade dysplasia; LGD: Low-grade dysplasia; IMC: Intramucosal adenocarcinoma.